Figure 5.
βla-M VLPs enveloped with the NiV-GE505A mutant recapitulate differential receptor usage. a) Enveloped βla-M VLPs incorporating an E505A mutation in NiV-G were used to infect CHO-B2 or CHO-B3 cells stably expressing only ephrin-B2 or ephrin-B3, respectively. Infected cells (% blue positive) were quantified using flow cytometry with ephrin-B2 mediated entry normalized as 100%. Data shown as an average of triplicates from three individual experiments ± SEM. b) VLPs from (5a) were lysed and blotted for protein incorporation using anti-HA (NiV-G/NiV-GE505A), anti-AU1 (NiV-F), or anti-NiV-M antibodies.